Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik has entered into an agreement to collaborate with researchers at the Mount Sinai School of Medicine, New York, to discover and evaluate novel, pharmaceutically active small molecules for new cancer targets.
Subscribe to our email newsletter
The collaboration will use Telik’s proprietary drug discovery technology, Trap (target-related affinity profiling), which enables the discovery of small molecule product candidates by taking advantage of the fundamental principle that pharmaceutically active molecules work by interacting with a protein target.
Trap can identify molecules that interact selectively with a disease-related protein target by screening as few as 200 computationally selected compounds, compared to as many as two million in traditional small molecule screening.
“I am pleased to be working with Telik to use the Trap technology for the translation of important advances in the basic understanding of cancer to potential therapeutic applications to benefit cancer patients,” said Dr Stuart Aaronson, professor and chair of oncological sciences and professor of medicine at the Mount Sinai School of Medicine, and principal investigator for this Trap collaboration. “The Trap technology may accelerate this progress.”